Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1756-8722
Umfang
Online-Ressource
Sprache
Englisch
Anmerkungen
online resource.

Erschienen in
Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk ; volume:13 ; number:1 ; day:20 ; month:8 ; year:2020 ; pages:1-11 ; date:12.2020
Journal of hematology & oncology ; 13, Heft 1 (20.8.2020), 1-11, 12.2020

Urheber
Weisel, Katja
Spencer, Andrew
Lentzsch, Suzanne
Avet-Loiseau, Hervé
Mark, Tomer M.
Spicka, Ivan
Masszi, Tamas
Lauri, Birgitta
Levin, Mark-David
Bosi, Alberto
Hungria, Vania
Cavo, Michele
Lee, Je-Jung
Nooka, Ajay
Quach, Hang
Munder, Markus
Lee, Cindy
Barreto, Wolney
Corradini, Paolo
Min, Chang-Ki
Chanan-Khan, Asher A.
Horvath, Noemi
Capra, Marcelo
Beksac, Meral
Ovilla, Roberto
Jo, Jae-Cheol
Shin, Ho-Jin
Sonneveld, Pieter
Casneuf, Tineke
DeAngelis, Nikki
Amin, Himal
Ukropec, Jon
Kobos, Rachel
Mateos, Maria-Victoria
Beteiligte Personen und Organisationen
SpringerLink (Online service)

DOI
10.1186/s13045-020-00948-5
URN
urn:nbn:de:101:1-2020111220210479811357
Rechteinformation
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
15.08.2025, 07:23 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Weisel, Katja
  • Spencer, Andrew
  • Lentzsch, Suzanne
  • Avet-Loiseau, Hervé
  • Mark, Tomer M.
  • Spicka, Ivan
  • Masszi, Tamas
  • Lauri, Birgitta
  • Levin, Mark-David
  • Bosi, Alberto
  • Hungria, Vania
  • Cavo, Michele
  • Lee, Je-Jung
  • Nooka, Ajay
  • Quach, Hang
  • Munder, Markus
  • Lee, Cindy
  • Barreto, Wolney
  • Corradini, Paolo
  • Min, Chang-Ki
  • Chanan-Khan, Asher A.
  • Horvath, Noemi
  • Capra, Marcelo
  • Beksac, Meral
  • Ovilla, Roberto
  • Jo, Jae-Cheol
  • Shin, Ho-Jin
  • Sonneveld, Pieter
  • Casneuf, Tineke
  • DeAngelis, Nikki
  • Amin, Himal
  • Ukropec, Jon
  • Kobos, Rachel
  • Mateos, Maria-Victoria
  • SpringerLink (Online service)

Ähnliche Objekte (12)

Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX

Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX

Autologous Stem Cell Collection after Daratumumab, Bortezomib, Thalidomide, and Dexamethasone versus Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma

Autologous Stem Cell Collection after Daratumumab, Bortezomib, Thalidomide, and Dexamethasone versus Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma

Treatment patterns for AL amyloidosis after frontline daratumumab, bortezomib, cyclophosphamide, and dexamethasone treatment failures

Treatment patterns for AL amyloidosis after frontline daratumumab, bortezomib, cyclophosphamide, and dexamethasone treatment failures

Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab (“Pom‐PAD‐Dara”) in relapsed/refractory multiple myeloma

Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab (“Pom‐PAD‐Dara”) in relapsed/refractory multiple myeloma

Bortezomib, lenalidomide, and dexamethasone versus bortezomib, doxorubicin, and dexamethasone in newly diagnosed multiple myeloma

Bortezomib, lenalidomide, and dexamethasone versus bortezomib, doxorubicin, and dexamethasone in newly diagnosed multiple myeloma

Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE

Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE

Daratumumab, lenalidomide, and dexamethasone in East Asian patients with relapsed or refractory multiple myeloma: subgroup analyses of the phase 3 POLLUX study

Daratumumab, lenalidomide, and dexamethasone in East Asian patients with relapsed or refractory multiple myeloma: subgroup analyses of the phase 3 POLLUX study

Bortezomib-induced hyponatremia: tolvaptan therapy permits continuation of lenalidomide, bortezomib and dexamethasone therapy in relapsed myeloma

Bortezomib-induced hyponatremia: tolvaptan therapy permits continuation of lenalidomide, bortezomib and dexamethasone therapy in relapsed myeloma

Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment

Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment

A real-life study of daratumumab-bortezomib-dexamethasone (D-VD) in lenalidomide exposed/refractory multiple myeloma patients: a report from the Triveneto Myeloma Working Group

A real-life study of daratumumab-bortezomib-dexamethasone (D-VD) in lenalidomide exposed/refractory multiple myeloma patients: a report from the Triveneto Myeloma Working Group

Daratumumab

Daratumumab

Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk

Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk

Verbundene Objekte